Vanguard Group Inc. Has $895.89 Million Stake in Glaukos Co. (NYSE:GKOS)

Vanguard Group Inc. lifted its stake in shares of Glaukos Co. (NYSE:GKOS) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,974,971 shares of the medical instruments supplier’s stock after buying an additional 101,838 shares during the period. Vanguard Group Inc. owned about 0.11% of Glaukos worth $895,887,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its position in Glaukos by 2.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 28,343 shares of the medical instruments supplier’s stock worth $3,693,000 after buying an additional 632 shares during the period. BNP Paribas Financial Markets increased its position in Glaukos by 186.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,726 shares of the medical instruments supplier’s stock valued at $1,788,000 after acquiring an additional 8,942 shares during the period. Cynosure Group LLC bought a new position in shares of Glaukos during the third quarter valued at $372,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Glaukos by 2.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,956 shares of the medical instruments supplier’s stock worth $1,427,000 after purchasing an additional 231 shares during the period. Finally, Public Sector Pension Investment Board grew its stake in shares of Glaukos by 5.1% in the third quarter. Public Sector Pension Investment Board now owns 116,605 shares of the medical instruments supplier’s stock worth $15,191,000 after purchasing an additional 5,700 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Down 1.6 %

GKOS opened at $101.97 on Friday. Glaukos Co. has a fifty-two week low of $88.16 and a fifty-two week high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company’s 50-day moving average is $130.52 and its 200 day moving average is $135.64. The firm has a market capitalization of $5.77 billion, a P/E ratio of -35.53 and a beta of 0.99.

Glaukos (NYSE:GKOS) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total transaction of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Stephens upgraded Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus raised their target price on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Wells Fargo & Company increased their target price on Glaukos from $153.00 to $160.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $140.00 to $200.00 in a research note on Wednesday, February 19th. Finally, UBS Group assumed coverage on shares of Glaukos in a research note on Friday, December 6th. They issued a “buy” rating and a $182.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus target price of $163.25.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.